[Erythropoietin - state of science]

Area of Science:

• Biotechnology
• Pharmacology
• Cardiovascular Medicine

Background:

• Erythropoietin (EPO) has a century of history in medical use.
• EPO gene cloning in 1984 led to FDA approval in 1989 for treating anemia in chronic kidney disease and malignancies.
• Recent research focused on improving EPO bioactivity, half-life, and exploring alternative applications.

Purpose of the Study:

• To review advancements in erythropoietin (EPO) therapeutics and applications.
• To highlight the potential of EPO in non-hematopoietic tissues for treating conditions like cardiovascular diseases.
• To address the ongoing issue of EPO abuse in sports due to detection challenges.

Main Methods:

• Review of scientific literature and clinical research on erythropoietin (EPO) over the past 15 years.
• Analysis of novel EPO analogues (e.g., SEP, CEPO, CERA) and their signaling pathways.
• Investigation into the expression and function of EPO receptors in non-hematopoietic tissues.

Main Results:

• Development of improved EPO variants with enhanced bioactivity and half-life.
• Discovery of EPO receptor and synthesis in non-hematopoietic tissues (heart, ovaries, glial cells).
• Identification of EPO's role in cell proliferation, differentiation, angiogenesis, and apoptosis inhibition, suggesting therapeutic potential for stroke and cardiac infarction.
• Concerns remain regarding the detectability of EPO abuse in sports due to new drug formulations.

Conclusions:

• Erythropoietin (EPO) offers expanded therapeutic potential beyond anemia, particularly in cardiovascular diseases and neurological conditions.
• Ongoing research into EPO analogues and non-hematopoietic functions presents new treatment avenues.
• The challenge of detecting EPO abuse in sports persists with the advent of new, undetectable formulations.